Terumo Expands CDMO Production Capacity with European Acquisition
Through the strategic acquisition of a facility from WuXi Biologics based in Germany, Terumo has strengthened its ability to serve both domestic and international pharmaceutical companies.
Reinforcing its position in the CDMO sector, Terumo Corporation has completed its acquisition of a drug product plant and associated quality control laboratory operations from WuXi Biologics. The strategically acquired plant is located in Leverkusen, Germany, and the transaction was officially closed on Sept. 30, 2025 (1).
“Our expanded footprint in Europe and unique CDMO capabilities will empower biopharmaceutical companies to bring effective treatments for chronic diseases to market more efficiently,” said Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, Terumo, in a company press release (1).
The Leverkusen plant comprises state-of-the-art facilities compliant with current good manufacturing practice (CGMP) standards and is staffed by skilled professionals with significant production expertise. Through the addition of these assets, Terumo will be able to offer fill/finish services, including device assembly, for vials and polymer prefillable syringes.
“With our integrated solution — from primary container and fill/finish capabilities to device assembly — customers can bring us their active pharmaceutical ingredient (API) and leave with fully assembled auto-injectors,” explained Marco Chiadò Piat, President, Pharmaceutical Solutions, Terumo, in the press release (1). “This is a win-win for both patients and healthcare system, as self-injection systems offer a more cost-effective and patient-friendly way to administer injectable drugs.”
In addition to strengthening its position as a CDMO, the new plant expands Terumo’s integrated service offerings and boosts its ability to support biopharmaceutical companies in launching injectable therapeutic products. Furthermore, the acquisition will provide Terumo with the capacity to meet growing demand for CDMO services, which have been driven by the expansion of the biopharmaceutical market.
Terumo and WuXi Biologics reached the agreement for the acquisition, in a deal worth a total of EUR 150 million (approximately USD 175 million), back in May 2025 (2). The Leverkusen facility adds a European-based offering to Terumo’s CDMO production bases at the Kofu, Fujinomiya, and Yamaguchi factories, which are all located in Japan.
“The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” commented Hikaru Samejima, Chief Executive Officer, Terumo Corporation, in a company press release about the agreement (2). “By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business.”
References
Terumo Europe. Terumo Announces Completion of Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany. Press Release, Oct. 1, 2025.
Terumo Europe. Terumo and WuXi Biologics Enter into Agreement on a Drug Product Plant in Leverkusen, Germany. Press Release, May 14, 2025.